Document:

Amendment #8 to Amended and Restated Development, License, and Supply Agreement

 Exhibit 10.15 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

AMENDMENT #8 
 TO AMENDED AND RESTATED DEVELOPMENT, 
 LICENSE AND SUPPLY
AGREEMENT 
 This Amendment # 8 effective as of the last date on the signature page hereof (“Amendment Effective
Date”), by and between CIMA LABS INC., a Delaware corporation (“CIMA”), and Azur Pharma Limited, an Irish limited company (“AZUR”), as assignee of Azur Pharma International III Limited, a Bermuda corporation, amends and
supplements that certain Amended and Restated Development, License and Supply Agreement between CIMA and AZUR dated August 22, 2005, as amended by that Amendment #1 effective October 19, 2005, Amendment #2 effective April 10, 2007,
Amendment #3 effective as of January 1, 2008, Amendment #4 effective as of April 15, 2008, Amendment #5 effective as of September 9, 2008, Amendment #6 effective as of March 6, 2009 (“Amendment #6), and Amendment #7
effective as of February 20, 2009 (“Amendment #7) (collectively, the “Agreement”). 
 WHEREAS, CIMA is
conducting development work with regard to potential 150mg and 200 mg dosage forms of the API formulated with the DuraSolv® technology pursuant to Schedule B-10 of the Agreement; 

WHEREAS, Amendment #6 provides that the parties are to mutually agree upon the price to be paid to CIMA by AZUR for 150 mg and 200 mg
tablets of Product manufactured by CIMA; and 
 WHEREAS, the parties have agreed upon such pricing, subject to successful
development and validation of the 150 mg and 200 mg dosage forms of the Product: 
 NOW, THEREFORE, the parties hereby agree to
amend the Agreement as follows: 
  

	 	1.	Schedule F of the Agreement is hereby replaced by Schedule F attached to this Amendment #8. 

 

	 	2.	Unless otherwise set forth in this Amendment #8, all references to Sections or Appendices refer to Sections or Appendices of the Agreement. 

 

	 	3.	In the event of any conflict between this Amendment #8 and the Agreement, the terms of this Amendment #8 shall control. 

 

	 	4.	All other terms and conditions of the Agreement shall remain in full force and effect. Except as expressly defined herein, all capitalized terms shall have the meanings
set forth in the Agreement. 

  
 Execution Version

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment 48 to be executed in two
originals by their duly authorized representatives. 

 

			
	 CIMA LABS INC.

		
	 BY:
	 	 /s/ Sarma
Duddu

			
		
	 NAME:
	 	 Sarma Duddu

			
		
	 TITLE:
	 	 General Manager, VP Worldwide Drug Delivery Technologies

		 
		
	 DATE:
	 	 9 March 2010

			
	 AZUR PHARMA LIMITED

		
	 BY:
	 	 /s/ Fintan
Keegan

			
		
	 NAME:
	 	 Fintan Keegan

			
		
	 TITLE:
	 	 SVP Technical
Ops

  

			
		
	 DATE:
	 	 12 March 2010

 

  
 Execution Version

 Amended and Restated Development, License and Supply Agreement 

Schedule F 

Cost of Goods 
 Pursuant to Sections 5,1, 5.3 and 5.6, Azur shall pay to CIMA for Product the amounts indicated on the following schedule in respect of CIMA’s manufacturing obligations hereunder. 

TRADE and SAMPLES (cost per tablet) 
  

											
	 Potency
	  	Total Cost-
Product for
Sale by Azur in
United
States
(1) (2)(4)	 	  	Total Cost-
Product for
sale by Azur in
European Union
(1) (2) (5)	 	  	 Packaging

	 12.5 mg
	  	 	***	  	  	 	***	  	  	 •    100 count bottles

	 25 mg
	  	 	***	  	  				  	 •    100 count bottles

•    6-count blister (bulk)

	 25 mg
	  	 	***	  	  				  	 •    6-count blister packaged in 48-ct. carton

	 25 mg (3)
	  				  	 	***	  	  	 •    6-count blister packaged in 30-ct carton

	 100 mg
	  	 	***	  	  				  	 •    100 count bottles

•    6-count blister (bulk)

	 100 mg
	  	 	***	  	  				  	 •    6-count blister packaged in 48-ct. carton

	 100 mg (3)
	  				  	 	***	  	  	 •    6-count blister packaged in 30-ct carton

	 150 mg (3)
	  	 	***	  	  				  	 •    100 count bottles

•    6-count blister (bulk)

	 150 mg (3)
	  	 	***	  	  				  	 •    6-count blister packaged in 48-ct. carton

	 150 mg (3)
	  				  	 	***	  	  	
	 200 mg (3)
	  	 	***	  	  				  	 •    100 count bottles

•    6-count blister (bulk)

	 200 mg (3)
	  	 	***	  	  				  	 •    6-count blister packaged in 48-ct. carton

	 200 mg (3)
	  				  	 	***	  	  	

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  
 Execution Version

	(1)	The cost per tablet does not include the cost of API. The parties acknowledge and agree that these prices are based upon one or two dose splits per batch. Each batch
will be packaged entirely in bottles or entirely in blisters as provided above. 

	(2)	 Per tablet costs will be adjusted annually each January 1st, commencing on January 1, 2009, but increases shall not exceed the PPI (Pharmaceutical) increase for the prior
year. “PPI (Pharmaceutical)” means the producer price index for Pharmaceutical and Medicine Manufacturing-Series pcu 325412325412 as published by the US Bureau of Labor Statistics, currently at http://www.bls.gov/ppi. If and when
this exact index is no longer available, the parties shall in good faith agree upon a comparable replacement index. 

	(3)	Subject to successful development and validation. 

	(4)	No variants for US product 

	(5)	*** Purchase orders must be supplied within 120 days in advance to accommodate ordering packaging materials. *** 

	(6)	To be mutually agreed upon by the parties, acting in good faith, if development and validation successful, dependent upon packaging configurations, variants, etc.

 PLACEBOS (cost per tablet) 
  

							
	 Placebo type
	  	Total Cost (1)	 	  	 Packaging

	 12.5 mg
	  	 	***	  	  	100 count bottles
	 25 mg
	  	 	***	  	  	100 count bottles or 6-count blisters (bulk)
	 25 mg
	  	 	***	  	  	6-count blister packaged in 48-ct. carton(2)(3)
	 100 mg
	  	 	***	  	  	100 count bottles or 6-count blisters (bulk)
	 100 mg
	  	 	***	  	  	6-count blister packaged in 48-ct. carton (2)(3)
	 150 mg (2)
	  	 	***	  	  	100 count bottles or 6-count blisters (bulk)
	 200 mg (2)
	  	 	***	  	  	100 count bottles or 6-count blisters (bulk)

  

	(1)	The parties acknowledge and agree that these prices are based upon one or two dose splits per batch. If Alamo would like CIMA to validate dose splits of more than two
per batch, the parties will mutually agree upon an appropriate increase in these prices. Each batch will be packaged entirely in bottles or entirely in blisters as provided above. 

	(2)	Subject to successful development and validation. 

	(3)	For sale in the United States. 

 

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  
 Execution VersionAmendment #9 to Amended and Restated Development, License, and Supply Agreement

 Exhibit 10.16 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

AMENDMENT #9 
 TO AMENDED AND RESTATED DEVELOPMENT, 
 LICENSE AND SUPPLY AGREEMENT

 This Amendment # 9 effective as of the last date on the signature page hereof and upon execution of the
Settlement and License Agreement (as defined below) (the “Amendment Effective Date”), by and between CIMA LABS INC., a Delaware corporation (“CIMA”), and Azur Pharma Limited, an Irish limited company (“AZUR”), as
assignee of Azur Pharma International III Limited, a Bermuda corporation, amends and supplements that certain Amended and Restated Development, License and Supply Agreement between CIMA and AZUR dated August 22, 2005, as amended by that
Amendment #1 effective October 19, 2005, Amendment #2 effective April 10, 2007, Amendment #3 effective as of January 1, 2008, Amendment #4 effective as of April 15, 2008, Amendment #5 effective as of September 9, 2008,
Amendment #6 effective as of March 6, 2009 (“Amendment #6), and Amendment #7 effective as of February 20, 2009 (“Amendment #7), and Amendment #8 effective as of March 12, 2010 (“Amendment #8) (collectively, the
“Agreement”). 
 WHEREAS, CIMA and AZUR are seeking to settle the CIMA/AZUR v. Barr litigation, Civil
Action No. 08-531(LPS) and 09-349 (LPS) (jointly with 08-531(LPS)), currently pending in the United States District Court for the District of Delaware (the “Pending Litigation”); and 

WHEREAS, CIMA and AZUR intend to enter into the Teva Settlement and License Agreement between CIMA and AZUR on one hand
and Teva/Barr on the other hand as part of such settlement of the Pending Litigation (the “Settlement and License Agreement”). 
 NOW, THEREFORE, the parties hereby agree to amend the Agreement as follows: 
 (1)
*** 
 (2) *** 
 *** 

  
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

  

 
*** 
 (a) *** 

(b) *** 
 (c) *** 
 (d) *** 

(e) *** 
 (f) *** 
 *** 

*** 

  
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

  
 2. 

 
*** 
 (3) *** 

(4) The introductory paragraph of Section 11.1 of the Agreement shall be deleted in its entirety and replaced with the following:

 “The term of this Agreement shall begin upon the Effective Date and unless sooner terminated as
hereinafter provided, shall end on January 2, 2020. Notwithstanding the foregoing, this Agreement may be terminated as follows:” 
 (5) Section 12.1 of the Agreement shall be deleted in its entirety and replaced with the following: 
 “Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns; provided, however, that
neither CIMA nor AZUR may assign any of its rights, duties or obligations hereunder without the prior written consent of the other, such consent shall not be unreasonably withheld; except that no prior written consent shall be required in the event
that a third party acquires substantially all of the assets or outstanding shares of, or merges with, AZUR or CIMA, as the case may be. 
 (6) Unless otherwise set forth in this Amendment #9, all references to Sections or Appendices refer to Sections or Appendices of the Agreement. 

(7) In the event of any conflict between this Amendment #9 and the Agreement, the terms of this Amendment #9 shall control. 

(8) All other terms and conditions of the Agreement shall remain in full force and effect. Except as expressly defined herein, all
capitalized terms shall have the meanings set forth in the Agreement. 
 [Rest of page intentionally left blank]

  
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

  
 3. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment #9 to be executed in two
originals by their duly authorized representatives. 

 

			
	CIMA LABS INC.
		
	 BY:
	 	 /s/ Derek Moe

			
		
	 Name:
	 	 Derek Moe

			
		
	 Title:
	 	 VP

			
		
	 Date:
	 	 06 JUL 2011

			
	        AZUR PHARMA LIMITED
		
	         BY:
	 	 /s/ Fintan
Keegan

			
		
	         Name:
	 	 Fintan Keegan

			
		
	         Title:
	 	 Senior Vice President, Technical Operations

			
		
	         Date:
	 	 5 July 2011

 

  
 4.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]